Skip to content

Systematic Screening for Deep Vein Thrombosis in Critically Ill Patients

Potential Harms and Benefits of Systematic Screening for Deep Vein Thrombosis in Critically Ill Patients

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05019092
Enrollment
100
Registered
2021-08-24
Start date
2021-01-01
Completion date
2021-12-31
Last updated
2021-08-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Deep Vein Thrombosis

Brief summary

Background: venous thromboembolism (VTE) is a common complication in critically ill patients, admitted to the Intensive Care Units (ICUs). At the present time, there is no validated score to estimate risks and benefits of antithrombotic pharmacological prophylaxis in this subset of patients. Aim of the study: investigating potential harms and benefits of a protocol for systematic screening of DVT in critically ill patients, admitted to an ICU. Expected relevance: systematic screening for deep vein thrombosis (DVT) through ultrasound (US) lower limb veins examination could help defining the indication to antithrombotic pharmacological treatment, but no protocol of systematic screening has been validated so far. Furthermore, the screening could be associated with over-diagnosis and consequent over-treatment, as well as increased management burden for the caregivers and higher healthcare costs.

Interventions

DIAGNOSTIC_TESTUltrasound examination of lower limb veins

Ultrasound examination will be performed by trained physicians using a commercially available ultrasound system and 5.0-15.0 MHz linear probe. The examinations consists of a comprehensive B-mode ultrasound protocol, from thigh to ankle, employing compression and color-Doppler at selected sites, according to the Consensus Conference of the Society of Radiologists in Ultrasound.

Sponsors

Ettore Marini
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SCREENING
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age \>18 years old * Admission to the ICU

Exclusion criteria

* duration of stay in ICU \<5 days * SARS-CoV-2 infection * established DVT or pulmonary embolism at admission * established coagulation disorder * presence of inferior vena cava filter at the admission * admission/discharge to the ICU of another hospital

Design outcomes

Primary

MeasureTime frameDescription
Incidence of deep vein thrombosishospitalization in UTI, an average of 10 daysDiagnosis of deep vein thrombosis

Secondary

MeasureTime frameDescription
Prophylaxis/ treatment of venous thromboembolism (VTE)hospitalization in UTI, an average of 10 daysNecessity of prophylaxis/ treatment of VTE and its possible modifications during the stay in Intensive Care Unit
Incidence of pulmonary embolismhospitalization in UTI, an average of 10 daysFindings of pulmonary embolism at contrast-enhanced CT scan
Occurrence of major bleedinghospitalization in UTI, an average of 10 daysAccording to the definition of the International Society of Thrombosis and Hemostasis
Occurrence of anemiahospitalization in UTI, an average of 10 daysReduction of hemoglobin \>2 g/dL without evidence of active bleeding
Progression of deep vein thrombosis (DVT)hospitalization in UTI, an average of 10 daysExtension of a previously diagnosed DVT to a more proximal site
Risk of death in ICUhospitalization in UTI, an average of 10 daysDeath
Risk of death within 3 months after hospital dischargeWithin 3 months after hospital dischargeDeath
Risk of new hospital admission within 3 months after hospital dischargeWithin 3 months after hospital dischargeNew hospital admission
Duration of ICU stayhospitalization in UTI, an average of 10 daysDuration of ICU stay

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 13, 2026